AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04690569 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MeMed BV
Description: The MeMed BV™ Test is an immunoassay that measures three non-microbial (host) proteins (TRAIL, IP-10, and CRP) in adult and pediatric serum samples. The test is intended for use in conjunction with clinical assessments and other laboratory findings as an aid to differentiate bacterial from viral infection. The test is indicated for use in patients presenting to the ED, urgent care center and inpatients with suspected acute bacterial or viral infection. The MeMed BV™ Test generates a numeric score that falls within discrete interpretation bins based on the increasing likelihood of bacterial infection. The MeMed BV™ test is intended for in vitro diagnostic use only.
Study NCT01553513 — intervention group
Intervention type: PROCEDURE
Intervention: Invasive coronary angiography
Description: ICA is performed via the femoral artery in three projections (RAO 30°, RAO 15° and LAO 45°) and, if necessary, also in further projections. All angiograms are recorded digitally and assessed quantitatively by two experienced readers, who are blinded to the PET/CT results (Quant-Cor, QCA, Siemens Medical Systems, Forchheim, Germany or Digital Cardiac Imaging Systems, Philips, Eindhoven, Netherlands). The mean stenosis of the vessel is assessed in two projections and the percentage of stenosis is calculated for each single segment. Stenoses are localized by means of the AHA (American Heart Association) classification. Occlusions of the vessels are documented and revascularization is performed immediately in patients with acute coronary syndrome (STEMI, NSTEMI).
Study NCT01553513 — intervention group
Intervention type: PROCEDURE
Intervention: Intravascular ultrasound and virtual histology
Description: During the procedure an intravascular ultrasound will be recorded in grayscale. Radiofrequency raw-data will be collected at the peak of the R-wave and a VH-IVUS data recorder is used to reconstruct a color-coded map. Acquired data will be evaluated with a dedicated software. The grayscale IVUS images will be analyzed frame by frame and used to measure the diameter of the vessel lumen, of the external elastic membrane (EEM) as well as plaque and media thickness (defined as EEM minus lumen). The plaque burden will be calculated.~A VH-IVUS analysis will be performed for each frame. Four plaque components will be color-coded: dense calcium white, the necrotic core red, fatty tissue light green and scar tissue dark green. color fractions are expressed as percentage of the plaque area and percentage of plaque volume.~Lesions will be classified: pathologic intima thickening, fibroatheroma with thin cap, fibroatheroma with thick cap, fibrotic plaque and fibro-calcified plaque.
Study NCT00136747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Study NCT00136747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT02597023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: Mitoquinone pill, 20 mg/day
Study NCT02326584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard dose cytarabine for induction
Description: 100 mg/m2/day Days 1-7
Study NCT01675284 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AT-301
Description: Inactivated H5N1 Influenza Virion Vaccine
Study NCT02326584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD33A
Description: Given intravenously Day 1 or Days 1 and 4 of each cycle
Study NCT03304340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional electrical stimulation (FES)
Description: Two dual-channel stimulators (MEDTRONIC Respond Select；Empi Inc) were connected with a program timer to form one stimulating unit for functional electrical stimulation (FES). FES was delivered with 0.3-ms pulses at 30 Hz, maximum tolerance intensity about 20 to 30 mA to cause visible muscle contraction.
Study NCT03304340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous nerve stimulation (TENS)
Description: Transcutaneous nerve stimulation (TENS) stimulator (BioTENS, Skylark Device \& Systems Co., Ltd,) was applied with 0.2 ms pulses, at 100 Hz in the constant mode within the subject'sensory level without muscle contraction, via (5 × 3.5 cm) electrodes attached to the motor points of quadriceps and tibialis anterior (TA) on the affected lower extremity.
Study NCT03304340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard rehabilitation (SR)
Description: The standard rehabilitation (SR) program was a part of a regular intervention in stroke center. The activities of SR performed including neurodevelopment facilitation techniques, range of motion exercises and movement re-learning exercises etc.
Study NCT01553513 — intervention group
Intervention type: OTHER
Intervention: Serum biomarkers
Description: A 20 ml blood sample will be obtained from each patient. The following biomarkers will be assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol, triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP, resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin, fetuin, FGF21.~ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum markers.
Study NCT02326584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: 60 mg/m2/day Days 1-3
Study NCT03304340 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard rehabilitation (SR)
Description: The standard rehabilitation (SR) program was a part of a regular intervention in stroke center. The activities of SR performed including neurodevelopment facilitation techniques, range of motion exercises and movement re-learning exercises etc.
Study NCT02671682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immunoadsorption
Study NCT02671682 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasmapheresis
Study NCT02326584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose cytarabine for consolidation
Description: 3g/m2 on Days 1, 3, and 5 of each cycle
Study NCT04226131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood Draw
Description: A study nurse will draw up to 150 mL of blood to measure erythrocyte sedimentation rate (ESR) and measures of immune cell function. ESR is a common hematology test that is a measure of inflammation.
Study NCT02597023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MitoQ
Description: Mitoquinone pill, 20 mg/day
Study NCT02597023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo pill with inert excipient, 1 time/day
Study NCT02597023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill with inert excipient, 1 time/day
Study NCT03165136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine : 200 mg twice a day
Study NCT03165136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo of hydroxychloroquine
Study NCT04226131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Disease Activity (DAS-28) Assessment
Description: Participants in the RA cohort will receive a 28-joint examination by the study physician to assess RA disease activity and report their overall health assessment.
Study NCT04237584 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Enzalutamide during Lead-in Period
Description: Participants will receive 12 weeks open-label lead-in ARB (enzalutamide) that will continue after double-blind randomization to radium-223 or placebo.
Study NCT04226131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skeletal Muscle Mitochondrial Respiratory Capacity
Description: Near-Infrared Spectroscopy (NIRS) will be used to measure oxidative capacity of forearm flexor digitorum profundus and medial gastrocnemius muscles using the PortaMon device (Artinis Medical Systems, The Netherlands). NIRS is a low-cost, non-invasive method that estimates muscle oxidative capacity by measuring oxygen consumption (mVO2) recovery kinetics via assessment of intramuscular oxy- and deoxy-hemoglobin concentration following a sequence of brief, rapid arterial cuff occlusions. NIRS measures mitochondrial oxidative function as the mVO2 recovery rate constant k. In the absence of blood flow, changes in muscle oxygenation occur via oxygen consumption alone. In persons without RA, this non-invasive approach is highly correlated with muscle respiratory capacity assessed via muscle biopsies using in situ permiabilized fiber bundles and the Oroboros O2k system.
Study NCT03126084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg of intravenous acetaminophen will be administered twice a day
Study NCT03126084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Bupivacaine
Description: 20 ml of 0.25% bupivacaine will be administered to the fascia of the transversus abdominis muscle under ultrasound guidance.
Study NCT03126084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Bupivacaine+Glucose
Description: 15mg of 0.5% bupivacaine will be administered to subarachnoid space through 25G spinal needle
Study NCT03126084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol HCl
Description: 50mg of intramuscular tramadol will be administered when pain score is greater than 3 according to NRS
Study NCT03126084 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal Hernia Repair
Description: Patients will undergo open inguinal hernia repair with one of the tension free mesh techniques
Study NCT03440216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: * temocillin: blood sampling every day for 7 days~* ceftriaxone: blood sampling 12h after administration for 7 days~* meropenem: blood sampling at 1h, 3h, 5h and 8h after initiation of the administration at days 1 and 2; one sampling at 8h on days 3 to 7
Study NCT03440216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue sampling (lung)
Description: Sampling of tissue (lung) when possible during treatment for measurement of the content in antibiotic (temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient)
Study NCT03440216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collection of fluid samples
Description: Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic ((temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient) concentration when possible during treatment
Study NCT04095286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMB new formulation (1 mg)
Description: AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.
Study NCT04226131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Muscle Biopsy
Description: After local anesthesia (xylocaine, 2%) is injected, a small incision will be made in the thigh. Four to six small pieces of muscle about the size of a pea will be surgically removed. The incision site will be closed using steri-strips and/or derma-bond, and a light dressing applied.
Study NCT04226131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Body Composition
Description: Body composition assessments include circumference measurements and the BOD POD®. Minimal waist circumference measurements will be taken using a tape measure.
Study NCT04226131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiopulmonary Exercise Test (CPET)
Description: Cardiorespiratory aerobic capacity (VO2 peak), will be assessed using a maximal treadmill test protocol with cardiopulmonary gas exchange. Subjects will be asked to exercise on a treadmill to their perceived maximum ability and effort during which time they will have a mouthpiece in their mouth to determine maximal oxygen use/consumption through breathing. For safety purposes the subject will be monitored by electrocardiogram (ECG) and their blood pressure will be measured at rest and throughout the exercise phase of this test.
Study NCT04226131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Strength Testing
Description: Strength assessments will include dynamometry-assessed grip and quadriceps strength (Cybex HUMAC NORM, Comp Sports Med, Inc., Stoughton, MA) tests
Study NCT04226131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Measures include global health, pain, fatigue, physical function, self-efficacy for disease management and sleep.
Study NCT04226131 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skeletal Muscle Biomechanical Property Assessment
Description: Passive skeletal muscle stiffness and elasticity measurements of bilateral biceps brachii, flexor carpi radialis, vastus lateralis, and tibialis anterior using mechanical deformation with myotonometry using the MyotonPro device.
Study NCT04266652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tooth block
Description: tooth root blocks were used to increase the bone width
Study NCT04266652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autogenous bone block
Description: autogenous bone block were used to increase the bone width
Study NCT03633552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: The patients will initially undergo surgery. Within 4 to 6 weeks after surgery, all patients will receive chemoradiation. After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meter body surface per day for the first 5 days of every 28 days). In the control group, the patients will receive 6 cycles of adjuvant Temozolomide (in the same dosage).
Study NCT03633552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: The patients will initially undergo surgery. Within 4 to 6 weeks after surgery, all patients will receive chemoradiation. After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meter body surface per day for the first 5 days of every 28 days). In the control group, the patients will receive 6 cycles of adjuvant Temozolomide (in the same dosage).
Study NCT00063882 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy (100/110)
Description: 100 Gy Palladium-103 (P-102) or 110 Gy Iodine-125 (I-125) seeds within 2-4 weeks of completion of external beam radiotherapy.
Study NCT00063882 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy (125/145)
Description: 125 Gy Palladium-103 (P-103) or 145 Gy Iodine-125 (I-125) seeds within 4 weeks of study entry.
Study NCT00063882 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Total dose of 45 Gy to the prostate and seminal vesicles as a daily dose of 1.8 Gy given 5 times per week. The prescribed dose is defined at the International Commission of Radiation Units and Measurements (ICRU) reference point. Both 3D-conformal radiation therapy (3DCRT) and intensity modulated radiation therapy (IMRT) are permitted.
Study NCT03756883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate and Salmeterol Inhalation Powder
Description: 100/50 mcg per actuation
Study NCT03756883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate and Salmeterol Inhalation Powder
Description: 100/50 mcg per actuation
Study NCT03756883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhalation Powder
Description: No active content
Study NCT00707421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac acetate
Study NCT00707421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorometholone
Study NCT00707421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: artificial lacrimal tears
Study NCT00328484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Activity Program
Description: The lifestyle activity program will consist of 35 exercise and counseling sessions spaced over 11 months. This program will use cognitive-behavioral strategies to encourage physical activity at home. Participants will receive information on how to deal with COPD symptoms (including shortness of breath), goal-setting, social support, and motivation. Participants will also receive follow-up telephone calls from the program staff for additional support.
Study NCT00328484 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: The 3-month exercise program will consist of 36 1-hour exercise training sessions, conducted 3 times a week for 12 weeks.
Study NCT01392326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (75 mg)
Description: Secukinumab (75 mg)
Study NCT01392326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (150 mg)
Description: Secukinumab (150 mg)
Study NCT01392326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo Comparator
Study NCT03527004 — intervention group
Intervention type: OTHER
Intervention: Survey on Use of Tobacco Products in the General Population
Description: Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Italy.
Study NCT03527004 — intervention group
Intervention type: OTHER
Intervention: Survey on Use of Tobacco Products in IQOS Users
Description: Online survey to describe patterns of use in IQOS users residing in Italy.
Study NCT03920306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral anti-acid treatment
Description: This study investigates a bundle of three commonly used treatments
Study NCT03201978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 1% CREAM
Description: It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
Study NCT03201978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK2894512 MATCHING VEHICLE CREAM
Description: It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
Study NCT03992547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-assisted Gait Training
Description: SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern.
Study NCT03388502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated Text Messaging (SMS) Bot (intervention group)
Description: Patients will be enrolled in an 'Automated Text Messaging (SMS) Bot (intervention group)' which is a computer program that sends patients timely reminders, instructions, and videos to help them prepare and recover from surgery.
Study NCT03388502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine perioperative education & teaching (control group)
Description: Patients will receive the 'Routine perioperative education \& teaching (control group)' and will not be enrolled in the physician-specific SMS bot.
Study NCT04237584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lead-in Enzalutamide followed by Radium-223/Enzalutamide
Description: After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
Study NCT03126084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% Bupivacaine
Description: 10 ml 0.25% bupivacaine will be administered quadratus lumborum muscle and erector spinae muscle
Study NCT04237584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lead-in Enzalutamide followed by Placebo/Enzalutamide
Description: After a 12-week lead-in period of open-label enzalutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label enzalutamide.
Study NCT04237584 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Darolutamide during Lead-in Period
Description: Participants will receive 12 weeks open-label lead-in darolutamide that will continue after double-blind randomization to radium-223 or placebo.
Study NCT04237584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lead-in Darolutamide followed by Radium-223/Darolutamide
Description: After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
Study NCT03583021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injectable Product
Description: Sugammadex of 3 mg/kg is injected.
Study NCT04237584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lead-in Darolutamide followed by Placebo/Darolutamide
Description: After a 12-week lead-in period of open-label darolutamide, participants will be randomized to double-blind radium-223 or placebo. Participants will continue on their randomized, open-label darolutamide.
Study NCT03864848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral Touch Implant
Description: The study population for this study will be comprised of patients who are to undergo cardiac surgery with a sternotomy (e.g. CABG) and who present moderate to severe ischemic or functional MR. In order to be considered eligible for the study, each patient must meet the conditions listed in the inclusion and none of the exclusion criteria.